GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » EV-to-FCF

FSD Pharma (FSD Pharma) EV-to-FCF : -1.03 (As of May. 16, 2024)


View and export this data going back to 2018. Start your Free Trial

What is FSD Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, FSD Pharma's Enterprise Value is $11.17 Mil. FSD Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.83 Mil. Therefore, FSD Pharma's EV-to-FCF for today is -1.03.

The historical rank and industry rank for FSD Pharma's EV-to-FCF or its related term are showing as below:

HUGE' s EV-to-FCF Range Over the Past 10 Years
Min: -303.51   Med: -0.62   Max: 0.08
Current: -1.04

During the past 9 years, the highest EV-to-FCF of FSD Pharma was 0.08. The lowest was -303.51. And the median was -0.62.

HUGE's EV-to-FCF is ranked worse than
100% of 518 companies
in the Drug Manufacturers industry
Industry Median: 24.625 vs HUGE: -1.04

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), FSD Pharma's stock price is $0.3255. FSD Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.470. Therefore, FSD Pharma's PE Ratio for today is At Loss.


FSD Pharma EV-to-FCF Historical Data

The historical data trend for FSD Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FSD Pharma EV-to-FCF Chart

FSD Pharma Annual Data
Trend Aug15 Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -2.73 -0.67 -0.32 -0.45 -2.93

FSD Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 -1.87 -1.74 -2.67 -2.93

Competitive Comparison of FSD Pharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, FSD Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FSD Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, FSD Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where FSD Pharma's EV-to-FCF falls into.



FSD Pharma EV-to-FCF Calculation

FSD Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11.173/-10.828
=-1.03

FSD Pharma's current Enterprise Value is $11.17 Mil.
FSD Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FSD Pharma  (NAS:HUGE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

FSD Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.3255/-0.470
=At Loss

FSD Pharma's share price for today is $0.3255.
FSD Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.470.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


FSD Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of FSD Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


FSD Pharma (FSD Pharma) Business Description

Traded in Other Exchanges
Address
199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9
FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The Company operates in two segments: Biotechnology and Strategic Investments.

FSD Pharma (FSD Pharma) Headlines

From GuruFocus